Gujarat Fluorochemicals — Two Companies in One: A Fluoropolymer Recovery and a Battery Bet

The State of Play

Gujarat Fluorochemicals (GFL) is really two businesses stapled together. One is a mature, world-class fluorine-chemistry maker — PTFE and other fluoropolymers, refrigerant gases, bulk chemicals — that has just clawed its way back from a brutal down-cycle to about ₹5,000 crore of revenue and a recovering ~24% margin. The other is a brand-new, cash-hungry bet to become the West’s main non-Chinese supplier of lithium-battery materials, a ₹6,000 crore project that today produces almost no revenue and only losses. The first business pays the bills and the dividend; the second is what the stock’s rich valuation (about 66 times earnings) is really pricing. The story of the last four quarters is the chemicals engine quietly recovering while management made the battery bet progressively more concrete — and pushed several of its own deadlines to the right.

The Company

GFL (ticker FLUOROCHEM), part of the INOXGFL group and led by MD Vivek Jain and Deputy MD Dr. Bir Kapoor, reports a single “Chemicals” segment sub-split into:

• Fluoropolymers — PTFE, PVDF, FKM, micro-powders and specialty grades, the largest and most profitable leg, selling into semiconductors, aerospace, automobiles, EVs and clean energy. GFL is among the top global players.
• Fluorochemicals / refrigerants — R-22, R-125, and the newly commissioned low-global-warming R-32.
• Bulk chemicals — caustic soda, chloromethanes; the commodity leg, kept for vertical integration.

Alongside sits the new vertical, housed in GFCL EV Products — battery materials: LiPF6 salt, electrolytes, additives, PVDF/PTFE binders, LFP cathode active material, and (newly added in FY26) natural-graphite anode material. The pitch is a fully integrated, non-China battery-materials platform aimed at the US and Indian supply chains.

Financially, the core is capital-intensive and currently spending ahead of returns: FY26 revenue ~₹4,996 crore and profit ~₹574 crore, ROCE ~10%, ROE ~7.8%, with three straight years of negative free cash flow as capex runs hot. Promoters have trimmed their stake from 63.8% to 61.4%, while domestic institutions more than doubled to ~13.5% — partly through the equity raise funding the battery business.

The Story So Far

The cleanest way to read GFL is as a chemical cycle (peak → trough → recovery) running underneath a steadily escalating new-energy bet.

FY23 — the cyclical peak

FY23 was the apex. Consolidated revenue jumped 44% to ₹5,685 crore at a ~35% operating margin, and profit hit ₹1,323 crore — powered by a refrigerant pricing spike and a US market that tripled to ₹1,499 crore. The battery business existed only as a balance-sheet line (subsidiaries “in the process of setting up” plants; battery-chemical revenue essentially nil). With peak cash flows, the company paid down debt. In hindsight, two things were stretched: receivables and that tripled US exposure — both set up for a hangover.

FY24 — the trough, and conviction through it

The hangover arrived. Revenue fell 25% to ₹4,281 crore, margin halved to ~22%, and profit collapsed 67% to ₹435 crore as customers destocked and the US business halved back to ₹811 crore. The notable thing is what management did into that trough: it raised capex ~40% (to ₹956 crore), raised the dividend (₹2 to ₹3 a share despite profit halving), and moved the battery-chemicals plant from “setting up” to “manufacturing,” booking its first token revenue (₹0.37 crore). Counter-cyclical conviction — invest through the down-cycle rather than retrench.

FY25 — the rebound, and the bet becomes the headline

FY25 was recovery-with-conviction. Revenue rose 11% to ₹4,737 crore, margin back to 24%, profit up 26% to ₹546 crore as fluoropolymers rebounded (“a turning point… following the destocking-driven softness,” per Dr. Kapoor) and R-22 refrigerant pricing firmed. But the real story moved to batteries. The group set out to “quadruple EBITDA within three years,” and the battery platform got hard numbers for the first time: a ₹6,000 crore outlay (₹1,300 crore already spent), commissioned LiPF6/electrolyte/PVDF/PTFE plants, signed long-term LiPF6 and binder contracts, full-cell validation with a leading electrolyte maker, and — crucially — a financing structure that didn’t strain the parent: a ₹1,000 crore equity-and-warrant raise at a ₹25,000 crore valuation for the EV business. The organising idea was explicit: become the credible non-China alternative in the global battery-materials chain, using in-house HF and IRA/OBBBA-compliant Moroccan fluorspar to qualify for US trade corridors. First commercial revenue was guided for the second half of FY26.

Q1 FY26 (call of 5 August 2025) — confident on both fronts

The year opened strong on chemicals: segment EBITDA up 33% to ₹354 crore at a 28% margin, fluoropolymers posting a record quarter. Management reiterated ~25% fluoropolymer growth for FY26 and said R-32 refrigerant production would start “several quarters ahead of schedule,” targeting 20,000 tonnes by year-end. On the new US tariffs (25%), it was sanguine — PTFE and most battery materials were exempt, and the specialised new fluoropolymers that were hit have “very few suppliers globally.” Battery revenue was still a trickle; meaningful contribution was an FY27 story.

Q2 FY26 (call of 11 November 2025) — peak optimism, and a claim that wouldn’t hold

The chemicals margin hit 32% — which management called “sustainable going forward” — even as tariff uncertainty deferred fluoropolymer orders. Two forward claims stand out for how they aged. First, management expected an anti-dumping duty on PTFE imports to be implemented and to let GFL capture “upward of 50–60%” of imports. Second, despite a plant fire, it held the R-32 line: 20,000 tonnes by March 2026. On batteries, LiPF6 prices had risen from ~$10 to ~$17/kg (a tailwind for a producer), India’s first LFP cathode plant was commissioned, and EV revenue was now expected “from Q4.”

Q3 FY26 (call of 12 February 2026) — “one of the most challenging” quarters

Reality intruded. Consolidated revenue dipped 1% and EBITDA fell 6% to ₹275 crore, dragged by refrigerants (R-22 quota cuts plus the delayed R-32 start). Two of Q2’s hopes broke: the PTFE anti-dumping duty was not approved by the Finance Ministry — “eroded a few percentage points from the growth we were looking at” — and the US tariff, while cut from 50% to 18% (a relief), had already deferred buying. The R-32 ramp slipped “a quarter to a quarter and a half.” But the battery bet got dramatically more concrete: the IFC approved a ₹430 crore investment, a sovereign fund approved $82 million, a new ~$216 million greenfield battery-materials project in Oman was announced, and LiPF6 commercial supplies began in December 2025 with repeat orders already in hand.

Q4 FY26 (call of 26 May 2026) — recovery on chemicals, an “inflection” on batteries

The chemicals engine finished strong: Q4 segment revenue up 11%, EBITDA up 13% to ₹353 crore, with fluoropolymers up 19% and R-32 production finally commenced in March 2026 (over 10,000 tonnes, optimal from April). But full-year fluoropolymer growth came in at ~15% — well short of the 25% promised at the start — and FY27 guidance was reset to 15–20%. The battery vertical hit “an important inflection point”: all phase-one capacity commissioned and contracted with “marquee anchor customers,” LiPF6 scaling with FY27+ orders, LFP cathode off-taken for its entire capacity (final qualification expected end-Q3 FY27), and a newly disclosed natural-graphite anode facility that, management claimed, lets GFL address ~70% of an LFP cell’s value — “one of the most integrated battery-materials platforms globally.” The cost of all this showed up too: EV-segment losses widened sharply (the quarterly P&L charge rose from ~₹20 crore to ~₹45 crore) as commissioned plants could no longer capitalise pre-operative expenses.

The threads worth lining up, because they define an honest chronicle:

• Fluoropolymer growth: “25%” (Q1, Q2) → ~15% actual FY26 → 15–20% FY27 guide. Effectively walked back.
• PTFE anti-dumping duty: “expect implementation, capture 50–60% of imports” (Q2) → “not accepted by the Finance Ministry” (Q3). A clean miss.
• R-32: “20,000 tonnes by end-FY26, ahead of schedule” → fire → slipped → production finally commenced March 2026 (>10,000 tonnes), full 20,000 over time.
• Battery timing: got steadily firmer (IFC ₹430 crore, $82m sovereign fund, Oman $216m, anchor off-take) but also more clearly back-ended — salt-led revenue in FY27, LFP from late FY27, a ₹100-crore-plus quarterly run-rate only exiting FY27, and “full earnings potential by FY29.”
• Working capital: drifted from a 120-day aspiration to a “realistic 170–180,” sitting around 201 days mid-year.

Where Things Stand

As of the May 2026 call, GFL’s two halves are at very different points. The chemicals business has recovered convincingly — fluoropolymers growing mid-teens with a ~15% price increase that stuck, refrigerants buttressed by the new R-32 line and firm R-22 pricing, margins back toward the high-20s/low-30s — and it generates the cash that funds everything else. The battery business is the swing factor: the platform is now built, commissioned and, importantly, contracted (LiPF6 orders, full LFP off-take, anchor customers), with the integration story extended to anode material. But it is still pre-revenue in any meaningful sense and currently a widening loss, with the real earnings — by management’s own guidance — arriving in FY28–FY29. The capital plan is large and firm: ₹3,150 crore of capex in FY27 alone (₹2,300 crore in EV, ₹850 crore in the core), toward a cumulative ₹6,000 crore EV outlay by FY28, underwritten by external funding (IFC, a sovereign fund) rather than the parent’s balance sheet. The whole thesis rests on a single macro bet — that the US and Europe will pay a non-Chinese supplier for battery materials, and that GFL’s integration and IRA/OBBBA-compliant feedstock make it that supplier. Whether the contracted volumes convert into the promised ~2x asset turns and 25%+ margins on schedule is what the next two years will decide. The dividend, held at ₹3 through the cycle, signals the management’s own confidence in getting there.

The Four Checks

1. Quality and moat. A decent business with a real but partial edge, in one half of it. The fluoropolymer leg is genuinely hard chemistry — top-five globally, integrated HF feedstock, specialty grades with “very few suppliers globally” and long qualification cycles, plus a tailwind from Western suppliers exiting the field. That is a switching-cost-and-know-how moat of the contestable kind. The other legs are weaker: refrigerants live or die by quotas and price spikes (R-125 went from ~$18 to ~$5 on a single duty change), and bulk chemicals are pure commodity. The cycle itself shows the limit of the moat — operating margin swung from 35% to 21% and back in three years, which fortress businesses don’t do. The battery platform could become a moat (first-mover non-China integration) but today it is a claim, not a demonstrated advantage.

2. Returns on incremental capital and runway. Currently the weak check. ROCE has sat near 10% for three straight years (against ~27% at the FY23 peak) and ROE is 7.8%, while free cash flow has been negative for three years running (₹-330, ₹-335, ₹-291 crore) as capex pours into the ₹6,000 crore battery build. So a rupee retained today demonstrably earns about 10% — below what most investors would call compounding. The runway argument is all prospective: management promises ~2x asset turns and 25%+ margins on the EV platform from FY28–29, with contracted off-take to back it. If that lands, incremental returns inflect; until then, the record shows large sums deployed at modest returns, dragged further by working capital drifting to ~201 days.

3. Capital allocation for the stage. Bold and mostly coherent, with quibbles. The good: counter-cyclical conviction (capex up ~40% in the FY24 trough), debt paid down at the peak, and a genuinely clever funding structure — the battery business raised ₹1,000 crore at a ₹25,000 crore subsidiary valuation, then drew the IFC (₹430 crore) and a sovereign fund ($82 million), so the parent’s balance sheet isn’t carrying the bet alone; borrowings of ₹2,290 crore against ₹7,855 crore of reserves remain moderate. No buybacks, and the dividend (held at ₹3, a ~0.08% yield, under 5% payout) is token — defensible during a build phase. The quibbles: deadlines on the bet keep sliding right, working capital ballooned past management’s own targets, screener flags possible capitalising of interest, and ₹3,150 crore of FY27 capex is committed before the platform has proven it earns its keep.

4. Price. Demanding to the point of priced-for-success. As of the June 2026 snapshot, the stock trades at ₹3,576 — 66.9 times earnings and 5.04 times book — for a business currently earning ~10% ROCE and 7.8% ROE. The recovered chemicals core (₹574 crore of FY26 profit, still below the FY23 peak of ₹1,323 crore) cannot justify that multiple on its own; the market is paying up-front for the battery platform to deliver its FY28–29 earnings on schedule, on a record where the company’s own near-term guidance (25% fluoropolymer growth, the PTFE duty, the R-32 timeline) has repeatedly slipped. The contracted off-take makes the bet more credible than a pure story stock, but at this price there is little room for the schedule to slip again.

Sources

• Earnings-call transcripts read (4): Q1 FY26 (5 Aug 2025), Q2 FY26 (11 Nov 2025), Q3 FY26 (12 Feb 2026), Q4/FY26 (26 May 2026). From screener/BSE-hosted filings.
• Annual reports read (high-signal sections + targeted full-text reads): FY23, FY24, FY25. Note: the FY23 and FY24 report extracts did not capture the chairman’s/MD’s letters or MD&A narrative (those pages did not survive PDF extraction) — FY23/FY24 framing is grounded in the financial statements, R&D annexes and subsidiary schedules; FY25 extracted in full and carries the first-person framing.
• Financial snapshot: screener.in (consolidated, FLUOROCHEM), logged-out session, fetched 2026-06-07.
• Research dump: vault/Sources/Earnings/Gujarat Fluorochemicals Ltd/ (_profile_digest.md, _concall_digest.md, _ar_digest.md, raw transcripts, annual-report sections, _snapshot.json, _manifest.json). Not published.